Format

Send to

Choose Destination
Osteoporos Int. 2019 Feb 7. doi: 10.1007/s00198-019-04853-7. [Epub ahead of print]

The efficacy and safety of menatetrenone in the management of osteoporosis: a systematic review and meta-analysis of randomized controlled trials.

Su S1,2, He N1,2, Men P1, Song C3, Zhai S4.

Author information

1
Department of Pharmacy, Peking University Third Hospital, 49 Huayuan North Road, Haidian District, Beijing, 100191, China.
2
Department of Pharmacy Administration and Clinical Pharmacy, School of Pharmaceutical Science, Peking University, Beijing, China.
3
Department of Orthopaedics, Peking University Third Hospital, Beijing, China.
4
Department of Pharmacy, Peking University Third Hospital, 49 Huayuan North Road, Haidian District, Beijing, 100191, China. zhaisuodi@163.com.

Abstract

In our systematic review and meta-analysis, we comprehensively evaluated menatetrenone in the management of osteoporosis. We found that menatetrenone decreased the ratio of undercarboxylated osteocalcin to osteocalcin (ucOC/OC) and improved lumbar BMD compared with placebo based on the 18 studies assessed. However, its benefit in fracture risk control was uncertain.

INTRODUCTION:

We performed a systematic review and meta-analysis of the efficacy and safety of menatetrenone in managing osteoporosis.

METHODS:

PubMed, Cochrane Library, Embase, ClinicalTrials.gov , and three Chinese literature databases (CNKI, CBM, Wanfang) were searched for relevant randomized controlled trials (RCTs) published before October 5, 2017, comparing menatetrenone with other anti-osteoporotic drugs or placebo in treating osteoporosis. The pooled risk ratio (RR) or mean difference (MD) and 95% confidence interval (CI) were calculated using fixed-effects or random-effects meta-analysis.

RESULTS:

Eighteen RCTs (8882 patients) were included. Pooled analyses showed that menatetrenone was more effective than placebo in improving lumbar bone mineral density (BMD) (five studies, N = 658, MD = 0.05 g/cm2, 95% CI 0.01 to 0.09 g/cm2) and decreasing ucOC/OC (two studies, N = 75, MD = - 21.78%, 95% CI - 33.68 to - 9.87%). Compared with placebo, menatetrenone was associated with a nonsignificantly decreased risk of vertebral fracture (five studies, N = 5508, RR = 0.87, 95% CI 0.64 to 1.20). Evidence on other anti-osteoporotic drugs as comparators was limited and revealed no significantly different effects of menatetrenone on BMD or fracture risks. Furthermore, compared with placebo, menatetrenone significantly increased the incidence of adverse events (AEs) (two studies, N = 1949, RR = 1.47, 95% CI 1.07 to 2.02) and adverse drug reactions (four studies, N = 6102, RR = 1.29, 95% CI 1.07 to 1.56). However, no significant difference in the incidence of serious AEs was found between menatetrenone and placebo.

CONCLUSIONS:

Menatetrenone significantly decreases ucOC and might improve lumbar BMD in osteoporotic patients. However, its benefit in fracture risk control is uncertain.

KEYWORDS:

Efficacy; Menatetrenone; Meta-analysis; Osteoporosis; Safety

PMID:
30734066
DOI:
10.1007/s00198-019-04853-7

Supplemental Content

Full text links

Icon for Springer
Loading ...
Support Center